GORE VIABAHN VBX balloon<b>-</b>expandable endovascular overlapping stent combined with VIABAHN overlapping stent for the successful treatment of long-segment iliac artery occlusive disease: a case report_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

WEN Xin ¹ , HUANG Ke ² , ZHAO Jichun ¹ , LUO Xin ¹ , LI Yiyuan ¹ , DU Xiaojiong ¹ , GUO Qiang ¹ , CHEN Xiyang ¹ ,  HUANG Bin ¹

1. Department of Vascular Surgery, West China Hospital of Sichuan University, Chengdu 610041, P. R. China;
2. West China School of Clinical Medicine, Sichuan University, Chengdu 610041, P. R. China;

Corresponding author：

HUANG Bin, Email: xgwkhb@126.com

Keywords：

arteriosclerosis obliterans of lower limbs; long segment occlusion of main iliac artery; complex lesions of the main iliac artery; endovascular therapy; combination therapy

DOI：

10.7507/1007-9424.202208006

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Main iliac artery disease is a common lesion that leads to arteriosclerosis and occlusion of the lower limbs. Effective treatment of complex main iliac artery disease has always been a difficult problem. The author’s team successfully treated a patient with long segment iliac artery occlusive disease from the left common iliac artery to the opening of the left femoral artery (118 mm) with Gore viabahn VBX balloon dilated intravascular covered stent and viabahn covered stent, and be reported.

Citation： WEN Xin, HUANG Ke, ZHAO Jichun, LUO Xin, LI Yiyuan, DU Xiaojiong, GUO Qiang, CHEN Xiyang, HUANG Bin. GORE VIABAHN VBX balloon-expandable endovascular overlapping stent combined with VIABAHN overlapping stent for the successful treatment of long-segment iliac artery occlusive disease: a case report. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(9): 1154-1159. doi: 10.7507/1007-9424.202208006 Copy

1.	Aboyans V, Ricco JB, Bartelink MEL, et al. Editor’s Choice-2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2018, 55(3): 305-368.
2.	Norgren L, Hiatt WR, Dormandy JA, et al Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC Ⅱ). J Vasc Surg, 2007, 45 Suppl S: S5-S67.
3.	Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol, 1991, 20(2): 384-392.
4.	Muntner P, Wildman RP, Reynolds K, et al. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care, 2005, 28(8): 1981-1987.
5.	Sentí M, Nogués X, Pedro-Botet J, et al. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation, 1992, 85(1): 30-36.
6.	O’Hare AM, Vittinghoff E, Hsia J, et al. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the heart and estrogen/progestin replacement study (HERS). J Am Soc Nephrol, 2004, 15(4): 1046-1051.
7.	McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA, 2001, 286(13): 1599-1606.
8.	Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev, 2007, 2007(4): CD000123. doi: 10.1002/14651858.CD000123.pub2.
9.	McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation, 2003, 107(5): 757-761.
10.	Bäck M, Jivegård L, Johansson A, et al. Home-based supervised exercise versus hospital-based supervised exercise or unsupervised walk advice as treatment for intermittent claudication: a systematic review. J Rehabil Med, 2015, 47(9): 801-808.
11.	Bendermacher BL, Willigendael EM, Teijink JA, et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev, 2006, (2): CD005263. doi: 10.1002/14651858.CD005263.pub2.
12.	Fakhry F, Spronk S, van der Laan L, et al. Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial. JAMA, 2015, 314(18): 1936-1944.
13.	Vemulapalli S, Dolor RJ, Hasselblad V, et al. Supervised vs unsupervised exercise for intermittent claudication: A systematic review and meta-analysis. Am Heart J, 2015, 169(6): 924-937.
14.	Greenhalgh RM, Belch JJ, Brown LC, et al. The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J Vasc Endovasc Surg, 2008, 36(6): 680-688.
15.	Timaran CH, Prault TL, Stevens SL, et al. Iliac artery stenting versus surgical reconstruction for TASC (TransAtlantic Inter-Society Consensus) type B and type C iliac lesions. J Vasc Surg, 2003, 38(2): 272-278.
16.	Groot Jebbink E, Holewijn S, Versluis M, et al. Meta-analysis of individual patient data after kissing stent treatment for aortoiliac occlusive disease. J Endovasc Ther, 2019, 26(1): 31-40.
17.	Krankenberg H, Zeller T, Ingwersen M, et al. Self-expanding versus balloon-expandable stents for iliac artery occlusive disease: the randomized ice trial. JACC Cardiovasc Interv, 2017, 10(16): 1694-1704.
18.	Kokkinidis DG, Foley TR, Cotter R, et al. Acute and midterm outcomes of antegrade vs retrograde crossing strategies for endovascular treatment of iliac artery chronic total occlusions. J Endovasc Ther, 2019, 26(3): 342-349.
19.	Mwipatayi BP, Thomas S, Wong J, et al. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg, 2011, 54(6): 1561-1570.
20.	Mwipatayi BP, Sharma S, Daneshmand A, et al. Durability of the balloon-expandable covered versus bare-metal stents in the covered versus balloon expandable stent trial (cobest) for the treatment of aortoiliac occlusive disease. J Vasc Surg, 2016, 64(1): 83-94.
21.	de Donato G, Bosiers M, Setacci F, et al. 24-month data from the BRAVISSIMO: A large-scale prospective registry on iliac stenting for TASC A & B and TASC C & D lesions. Ann Vasc Surg, 2015, 29(4): 738-750.
22.	Suzuki K, Mizutani Y, Soga Y, et al. Efficacy and safety of endovascular therapy for aortoiliac TASC D lesions. Angiology, 2017, 68(1): 67-73.
23.	Feldman DN, Armstrong EJ, Aronow HD, et al. SCAI guidelines on device selection in Aorto-Iliac arterial interventions. Catheter Cardiovasc Interv, 2020, 96(4): 915-929.

1. Aboyans V, Ricco JB, Bartelink MEL, et al. Editor’s Choice-2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS). Eur J Vasc Endovasc Surg, 2018, 55(3): 305-368.
2. Norgren L, Hiatt WR, Dormandy JA, et al Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC Ⅱ). J Vasc Surg, 2007, 45 Suppl S: S5-S67.
3. Fowkes FG, Housley E, Cawood EH, et al. Edinburgh Artery Study: prevalence of asymptomatic and symptomatic peripheral arterial disease in the general population. Int J Epidemiol, 1991, 20(2): 384-392.
4. Muntner P, Wildman RP, Reynolds K, et al. Relationship between HbA1c level and peripheral arterial disease. Diabetes Care, 2005, 28(8): 1981-1987.
5. Sentí M, Nogués X, Pedro-Botet J, et al. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes. Circulation, 1992, 85(1): 30-36.
6. O’Hare AM, Vittinghoff E, Hsia J, et al. Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the heart and estrogen/progestin replacement study (HERS). J Am Soc Nephrol, 2004, 15(4): 1046-1051.
7. McDermott MM, Greenland P, Liu K, et al. Leg symptoms in peripheral arterial disease: associated clinical characteristics and functional impairment. JAMA, 2001, 286(13): 1599-1606.
8. Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev, 2007, 2007(4): CD000123. doi: 10.1002/14651858.CD000123.pub2.
9. McDermott MM, Guralnik JM, Greenland P, et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation, 2003, 107(5): 757-761.
10. Bäck M, Jivegård L, Johansson A, et al. Home-based supervised exercise versus hospital-based supervised exercise or unsupervised walk advice as treatment for intermittent claudication: a systematic review. J Rehabil Med, 2015, 47(9): 801-808.
11. Bendermacher BL, Willigendael EM, Teijink JA, et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev, 2006, (2): CD005263. doi: 10.1002/14651858.CD005263.pub2.
12. Fakhry F, Spronk S, van der Laan L, et al. Endovascular revascularization and supervised exercise for peripheral artery disease and intermittent claudication: a randomized clinical trial. JAMA, 2015, 314(18): 1936-1944.
13. Vemulapalli S, Dolor RJ, Hasselblad V, et al. Supervised vs unsupervised exercise for intermittent claudication: A systematic review and meta-analysis. Am Heart J, 2015, 169(6): 924-937.
14. Greenhalgh RM, Belch JJ, Brown LC, et al. The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J Vasc Endovasc Surg, 2008, 36(6): 680-688.
15. Timaran CH, Prault TL, Stevens SL, et al. Iliac artery stenting versus surgical reconstruction for TASC (TransAtlantic Inter-Society Consensus) type B and type C iliac lesions. J Vasc Surg, 2003, 38(2): 272-278.
16. Groot Jebbink E, Holewijn S, Versluis M, et al. Meta-analysis of individual patient data after kissing stent treatment for aortoiliac occlusive disease. J Endovasc Ther, 2019, 26(1): 31-40.
17. Krankenberg H, Zeller T, Ingwersen M, et al. Self-expanding versus balloon-expandable stents for iliac artery occlusive disease: the randomized ice trial. JACC Cardiovasc Interv, 2017, 10(16): 1694-1704.
18. Kokkinidis DG, Foley TR, Cotter R, et al. Acute and midterm outcomes of antegrade vs retrograde crossing strategies for endovascular treatment of iliac artery chronic total occlusions. J Endovasc Ther, 2019, 26(3): 342-349.
19. Mwipatayi BP, Thomas S, Wong J, et al. A comparison of covered vs bare expandable stents for the treatment of aortoiliac occlusive disease. J Vasc Surg, 2011, 54(6): 1561-1570.
20. Mwipatayi BP, Sharma S, Daneshmand A, et al. Durability of the balloon-expandable covered versus bare-metal stents in the covered versus balloon expandable stent trial (cobest) for the treatment of aortoiliac occlusive disease. J Vasc Surg, 2016, 64(1): 83-94.
21. de Donato G, Bosiers M, Setacci F, et al. 24-month data from the BRAVISSIMO: A large-scale prospective registry on iliac stenting for TASC A & B and TASC C & D lesions. Ann Vasc Surg, 2015, 29(4): 738-750.
22. Suzuki K, Mizutani Y, Soga Y, et al. Efficacy and safety of endovascular therapy for aortoiliac TASC D lesions. Angiology, 2017, 68(1): 67-73.
23. Feldman DN, Armstrong EJ, Aronow HD, et al. SCAI guidelines on device selection in Aorto-Iliac arterial interventions. Catheter Cardiovasc Interv, 2020, 96(4): 915-929.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

GORE VIABAHN VBX balloon-expandable endovascular overlapping stent combined with VIABAHN overlapping stent for the successful treatment of long-segment iliac artery occlusive disease: a case report

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content